Notice of Termination of RFA-FD-14-002 "The Use of Polyethylene Glycol in the Pediatric Population (R01)"
Notice NOT-FD-14-012 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 5, 2014 Category: Research Source Type: funding
The Use of Polyethylene Glycol in the Pediatric Population (R01)
Funding Opportunity Number: RFA-FD-14-088 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: Consumer ProtectionFood and NutritionHealthCFDA Number: 93.103Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits...
Source: Grants.gov - June 5, 2014 Category: Research Tags: Consumer Protection Food and Nutrition Health Source Type: funding
The Use of Polyethylene Glycol in the Pediatric Population (R01)
Funding Opportunity RFA-FD-14-088 from the NIH Guide for Grants and Contracts. The purpose of the proposed study is to better understand the extent of pediatric accumulation of low molecular weight (LMW) species that may be found in PEG 3350 products (e.g., ethylene and diethylene glycol) and of PEG 3350 metabolites.PEG 3350 products are used in the treatment of constipation. If present in the product when administered and/or produced in the gut and absorbed, these metabolites and LMW species may accumulate in children taking PEG 3350 products -- potentially leading to adverse events. This is an important first step ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 4, 2014 Category: Research Source Type: funding
Characterization of Critical Quality Attributes for Semisolid Topical Drug Products
The objective of this work is to support the development of regulatory standards and guidance's for industry regarding the development of semisolid topical drug products, based upon well-defined critical quality and performance attributes that best characterize these products.
DETAILED DESCRIPTION:
A preliminary classification system will be developed to comprehensively inventory the various types of semisolid dosage forms relevant to topical drug products, differentiated based upon their components and anticipated microstructures (e.g. single vs. multi-phase gels, oleaginous suspensions, pluronic lecithin organogels, ...
Source: Grants.gov - March 31, 2014 Category: Research Tags: Health Science and Technology and other Research and Development Source Type: funding
Notice of Change to Application Due Date and Expiration Date for RFA-FD-14-002 "The Use of Polyethylene Glycol in the Pediatric Population (R01)"
Notice NOT-FD-14-004 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 24, 2014 Category: Research Source Type: funding
The Use of Polyethylene Glycol in the Pediatric Population (R01)
Funding Opportunity Number: RFA-FD-14-002 Opportunity Category: DiscretionaryFunding Instrument Type: GrantCategory of Funding Activity: Consumer ProtectionHealthCFDA Number: 93.103Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3...
Source: Grants.gov - January 15, 2014 Category: Research Tags: Consumer Protection Health Source Type: funding
The Use of Polyethylene Glycol in the Pediatric Population (R01)
Funding Opportunity RFA-FD-14-002 from the NIH Guide for Grants and Contracts. The purpose of the proposed study is to better understand the extent of pediatric absorption of low molecular weight species that may be found in PEG 3350 products (e.g., ethylene and diethylene glycol). PEG 3350 products are used in the treatment of constipation. These low molecular weight species may be absorbed by children taking PEG 3350 products, potentially leading to adverse events. This is an important first step needed to begin to understand if PEG 3350 use contributes to adverse events in children due to the absorption of these s...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 14, 2014 Category: Research Source Type: funding
